Description
Tesamorelin is a modified version of GHRH — the brain’s own signal that tells the pituitary gland to release growth hormone. The modification makes it resistant to the enzyme that normally breaks GHRH down quickly in the bloodstream, giving it a longer window of activity. Because it works by stimulating the body’s own growth hormone production rather than supplying GH directly, it preserves the natural feedback systems that regulate GH levels.
What the research has found
• Clinical trials in subjects with HIV-associated fat redistribution showed tesamorelin produced significant and measurable reductions in visceral (abdominal) fat volume as measured by CT scan, along with improvements in lipid profiles, compared to placebo over 26–52 week periods (Falutz et al., 2010)
• Mechanistic research confirmed these fat-reducing effects work through GH-stimulated lipolysis — the direct breakdown of fat stored in adipose tissue — rather than water loss or redistribution, with corresponding increases in free fatty acid release from fat cells (Stanley et al., 2014)
• A key finding in pharmacokinetic studies was that tesamorelin’s N-terminal chemical modification extends its half-life from approximately 7 minutes (for natural GHRH) to approximately 30 minutes — a substantial improvement that underpins its research utility as a stable GHRH analogue (Stanley et al., 2014)
• Because tesamorelin acts upstream at the pituitary rather than delivering GH directly, studies confirmed it maintains the body’s natural GH feedback loop — an important distinction from direct GH administration in research models (Stanley et al., 2014)
For research use only. Not intended for use in humans or animals.
References
Falutz, J., et al. (2010). https://pubmed.ncbi.nlm.nih.gov/20393159/
Stanley, T. L., & Grinspoon, S. K. (2014). https://pubmed.ncbi.nlm.nih.gov/24423315/











